Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
9.1.2023 19:00:00 EET | Business Wire | Press release
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune cell-targeting compounds, further strengthening the company’s pipeline.
Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients. 3T‘s platform aims to address this challenge by identifying novel shared T-cell receptor (TCR) targets of productive immune responses and comprehensively screening TCRs and TCR mimetics for specificity and off-target cross-reactivities. The platform identifies the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning. This may lead to tumor-specific, safer therapies that can be delivered at higher doses.
“At Boehringer Ingelheim, we are committed to transforming patients’ lives. Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology + Immune Modulation, Boehringer Ingelheim.
“On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. “3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumor indications and across patient populations.”
Under the agreement, Boehringer Ingelheim will provide patient-derived TCR data to fuel 3T’s target discovery efforts to identify antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones totaling $268 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
For the full press release and link to “Notes to Editors” please click here:
Press Release
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005420/en/
Contact information
Media contacts:
B
oehringer Ingelheim
Dr. Reinhard Malin
Boehringer Ingelheim Corporate Center GmbH
Innovation Unit/Bio Comms, Corp. Affairs
Media + PR
press@boehringer-ingelheim.com
Linda Ruckel
Boehringer Ingelheim Corporate Center GmbH
Innovation Unit/Bio Comms, Corp. Affairs
Media + PR
P: 203-791-6672
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme Raises SEK 75 Million to Advance Its Commercial Biomanufacturing Strategy23.9.2026 15:07:00 EEST | Press release
Enginzyme AB has closed a new equity round raising SEK 75 million. The round marks a key milestone in the company's shift from R&D to a commercially driven strategy. "With our growth strategy established, closing this new investment round was a priority for enginzyme," said Aymeric de Gantes, enginzyme's CEO. "We are also very excited to welcome new shareholders with complementary expertise, who will all contribute to our mission to deliver biomanufacturing solutions for the personal care, food, and pharmaceutical industries. Our technology enables lower cost in use for higher-quality ingredients, obtained through more sustainable manufacturing processes." Lotus One Investment Pte. Ltd. and Valquest Partners Europe are joining the company as new shareholders and members of the Board of Directors. Sofinnova Partners, Stiftelsen Industrifonden, Navigare Ventures AB and Almi Invest GreenTech were key participants, combined with several other new and existing shareholders. On Thursday, Sep
SLB Awarded Major Contract by OQEP for Integrated Facility Expansion in Oman23.9.2026 15:04:00 EEST | Press release
SLB (NYSE: SLB) has been awarded a contract by OQ Exploration & Production (OQEP) to deliver the Bisat-B Expansion Production Facility in Oman. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922635677/en/ SLB has been awarded a contract by OQ Exploration & Production (OQEP) to deliver the Bisat-B Expansion Production Facility in Oman. Under the contract, SLB will provide design, engineering, procurement, construction and commissioning services for the facility, along with four years of operations and maintenance support. Under the contract, SLB will provide design, engineering, procurement, construction and commissioning services for the facility, along with four years of operations and maintenance support. The expansion will increase the facility’s gross fluids handling capacity to 548,000 barrels per day. The project is scheduled for completion within 19 months. The award marks the next phase of development for the Bisa
Datavault AI Announces Rights Offering to Shareholders23.9.2026 15:03:00 EEST | Press release
Datavault AI Inc. (Nasdaq: DVLT) (“Datavault AI” or the “Company”), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing and tokenization technologies, today announced that its board of directors (the “Board”) has approved a rights offering to holders of its common stock (“Common Stock”) and certain other Datavault AI securities. Moody Capital Solutions, Inc. (“Moody Capital”) will act as dealer manager for the rights offering. The Rights Offering to include investors in a process usually reserved exclusively for banks Under the rights offering, the Company will distribute, at no charge, transferable subscription rights to holders of record of Common Stock and certain other Company securities with a contractual right to participate in the distribution. The Company has set a record date of October 9, 2026 for such offering (the “Record Date”). Such holders will receive one subscription right for a Common Unit for each share of Common Stock owned
Copeland Completes Acquisition of Dickson, Advancing Cold Chain Intelligence for Healthcare and Life Sciences23.9.2026 15:00:00 EEST | Press release
Copeland, a global leader in compression technologies and controls solutions, today announced it has completed the acquisition of Dickson, a Chicago-based provider of environmental monitoring and compliance technology solutions for highly regulated life sciences and healthcare environments. Increasing regulatory demands across the pharmaceutical and life sciences cold chain require continuous visibility from production through final delivery. Together, Dickson’s cloud-native monitoring platform and Copeland’s controls, monitoring and enterprise software solutions will enable a more connected, intelligent and compliant cold chain. “We are pleased to welcome our new colleagues from Dickson into Copeland,” said Ross B. Shuster, CEO of Copeland. “The acquisition of Dickson further strengthens our ability to serve customers across every stage of the healthcare and life sciences cold chain, from pharmaceutical manufacturing through distribution and patient care.” Enabling a Smarter, More Con
Sitetracker and 5x5 Break the Price Barrier for Portfolio-Scale Digital Twins and Asset Intelligence23.9.2026 13:11:00 EEST | Press release
Sitetracker and 5x5 Technologies today introduced a data-to-twin workflow that gives wireless infrastructure owners a practical, affordable path to digitizing an entire tower portfolio. The Sitetracker platform now integrates 5x5 Synthetic Twin technology, providing scalable asset intelligence at a price up to 85% less than traditional site modeling methods. Synthetic Twins leverage Sitetracker’s leading tower portfolio and operational data to create interactive 3D models of towers, rooftops and ground compounds providing tower operators with a baseline of their portfolio that can be progressively enriched as the site conditions evolve. This data when combined with Scout, Sitetracker’s Agentic AI platform, opens the opportunity for digitized workflows and unparalleled understanding of the asset portfolio. Why it matters AI-driven data demand, more spectrum deployments, and denser infrastructure are raising the bar for tower operations. Towercos need precise knowledge of each site: what
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom